Roz Sutton appointed as Senior Director of Regulatory Affairs at tranScrip
tranScrip is delighted to announce the appointment of Roz Sutton as Senior Director of Regulatory Affairs. Roz brings two decades of experience in Global Regulatory Affairs, having held leadership roles at top pharmaceutical companies including Roche and GSK, as well as in regulatory consultancy at DLRC. Her appointment underscores tranScrip’s commitment to strengthening its regulatory team as it continues to expand its expertise and service offerings.
A highly experienced regulatory strategist, Roz has led regulatory initiatives across key therapeutic areas such as ophthalmology, neurosciences, oncology, and rare diseases. She joins tranScrip as a key member of the Regulatory Affairs Senior Leadership team, which will drive the ongoing expansion of tranScrip's strategic and operational regulatory capabilities worldwide.
Roz joins tranScrip from Roche, where she led a team of regulatory specialists overseeing global regulatory programmes across all phases of drug development activities including accelerated approval pathways, special designations, paediatric strategies and cultivating strong relationships with health authorities. Notably, she spearheaded the design and implementation of Roche’s Early Talent Programme, which has been shortlisted as a finalist in the 2024 TOPRA Education Category.
Karen Nugent, Chief Operating Officer at tranScrip, commented: “We are delighted to welcome Roz to tranScrip. Roz’s extensive global regulatory expertise, coupled with her proven leadership skills, will be instrumental in advancing our regulatory affairs capabilities. Her appointment demonstrates tranScrip’s commitment to continue to build our expert team with a sharp focus on how we best support our clients' needs and further establish ourselves as a leading pharmaceutical consultancy.”
Roz shared her excitement about joining tranScrip: “I am thrilled to be part of such an innovative and dynamic team. tranScrip is well-recognised for its excellence in regulatory affairs and collectively for drug development know-how. I look forward to working alongside its talented experts and contributing to the company’s ongoing success and growth.”
As tranScrip continues to expand its regulatory expertise and services, Roz’s appointment further strengthens the company’s position as a trusted partner in delivering high-quality regulatory and drug development solutions.
For more information about tranScrip and its services, please visit www.transcrip-group.com.
